全文获取类型
收费全文 | 32296篇 |
免费 | 3441篇 |
国内免费 | 935篇 |
专业分类
耳鼻咽喉 | 280篇 |
儿科学 | 176篇 |
妇产科学 | 2121篇 |
基础医学 | 3219篇 |
口腔科学 | 1167篇 |
临床医学 | 2791篇 |
内科学 | 1264篇 |
皮肤病学 | 101篇 |
神经病学 | 2106篇 |
特种医学 | 1305篇 |
外国民族医学 | 25篇 |
外科学 | 6185篇 |
综合类 | 5984篇 |
现状与发展 | 9篇 |
预防医学 | 1451篇 |
眼科学 | 1625篇 |
药学 | 1625篇 |
43篇 | |
中国医学 | 1347篇 |
肿瘤学 | 3848篇 |
出版年
2024年 | 39篇 |
2023年 | 542篇 |
2022年 | 783篇 |
2021年 | 1352篇 |
2020年 | 1405篇 |
2019年 | 1070篇 |
2018年 | 1053篇 |
2017年 | 1395篇 |
2016年 | 1478篇 |
2015年 | 1446篇 |
2014年 | 2700篇 |
2013年 | 2367篇 |
2012年 | 2299篇 |
2011年 | 2483篇 |
2010年 | 1967篇 |
2009年 | 1729篇 |
2008年 | 1589篇 |
2007年 | 1593篇 |
2006年 | 1449篇 |
2005年 | 1151篇 |
2004年 | 889篇 |
2003年 | 804篇 |
2002年 | 644篇 |
2001年 | 570篇 |
2000年 | 392篇 |
1999年 | 338篇 |
1998年 | 293篇 |
1997年 | 255篇 |
1996年 | 260篇 |
1995年 | 245篇 |
1994年 | 226篇 |
1993年 | 178篇 |
1992年 | 168篇 |
1991年 | 156篇 |
1990年 | 134篇 |
1989年 | 111篇 |
1988年 | 128篇 |
1987年 | 98篇 |
1986年 | 115篇 |
1985年 | 117篇 |
1984年 | 132篇 |
1983年 | 109篇 |
1982年 | 108篇 |
1981年 | 84篇 |
1980年 | 65篇 |
1979年 | 44篇 |
1978年 | 48篇 |
1977年 | 23篇 |
1976年 | 17篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
1.
目的通过测量锁骨钩钢板内固定术后患者影像学资料,分析发生肩峰骨侵蚀的原因是否与钢板钩-肩峰匹配度相关。
方法回顾性分析2015年8月1日至2018年8月31日期间在上海市浦东医院骨科就诊的210例患者的影像学资料,210例患者均因肩锁关节脱位或锁骨远端骨折行锁骨钩钢板内固定治疗,其中男110例、女100例;年龄24~76岁,平均(44.60±8.75)岁;肩锁关节脱位70例,锁骨远端骨折140例。测量术后及终末随访患者肩锁关节正位X线片相关数据,按锁骨钩钢板术后是否发生肩峰骨侵蚀,将纳入患者分为3组:无骨侵蚀组(A组)、伴钢板钩移位骨侵蚀组(B组)、不伴移位的骨侵蚀组(C组),分别测量钢板钩-肩峰的匹配度(β),统计分析术后发生肩峰骨侵蚀与钢板钩-肩峰匹配度之间的关系。
结果纳入研究的210例患者术后随访24~64周,平均(32.0±6.5)周。A组患者115例,B组患者54例,C组患者41例。A组匹配度β(3.72±0.48)mm与B组β1(6.91±0.84)mm比较差异有统计学意义(P<0.05);A组匹配度β(3.72±0.48)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05);B组匹配度β1(6.91±0.84)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05)。
结论锁骨钩钢板内固定术后是否发生肩峰骨侵蚀与钢板钩-肩峰匹配度β存在明显相关性,钢板钩与肩峰之间的匹配度越好,β值越小,发生肩峰骨侵蚀的可能性更小。 相似文献
2.
3.
4.
目的:分析子野个数限值对宫颈癌固定野调强放疗(fixed-field intensity-modulated radiotherapy,ff-IMRT)计划的影响,寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者,基于Monaco 5.11.03计划系统,以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划(ff-IMRT计划依据子野个数限值命名,子野个数限值分别为40、60、70、80、100、120、130、150),采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后,plan40和plan60的D2%、Dmin、CI和HI均劣于plan100(P<0.05)。8种ff-IMRT计划均能较好保护危及器官(organ at risk,OAR)和正常组织。plan40小肠V45;plan40和plan60小肠D2cc,直肠、膀胱V45、D40%,两侧股骨头V40和正常组织 V35、V40均高于plan100(P<0.05)。plan40和plan60优化时间、治疗参数均优于plan100(P<0.05);plan120、plan130和plan150子野面积、子野个数(51~150 cm2和>150 cm2)和出束时间均劣于plan100(P<0.05)。结论:子野个数限值为70~100时,ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化,建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。 相似文献
5.
目的:分析我院2020年1月1日至2020年9月中旬近4万余例女性HPV感染情况,为HPV疫苗接种、宫颈病变预防、治疗、随访提供流行病学数据。方法:选取我院2020年1月1日至2020年9月中旬之间,于我院妇科门诊及病房、皮肤科门诊及体检中心的37 325接受HPV分型检测的患者的临床资料,分析检测结果。结果:HPV感染率为13.91%(5 193/37 325),单一感染率11.46%(4 276/37 325),阳性构成比82.34%(4 276/5 193),高危亚型感染以HPV16最多见,其次52、58,低危型以6最多见,其次为11、44,与5年前HPV感染情况分析中最常见的低危亚型为cp8304不同。不同年龄段感染率不同。结论:近年沈阳地区妇女HPV感染率为13.91%,较5年前感染率18.60%有所下降,以单一、高危亚型感染为主,多重感染并存为特征。 相似文献
6.
7.
Li Dong Mari Nygård Nathalie C. Støer Ole Klungsøyr Bo T. Hansen 《International journal of cancer. Journal international du cancer》2023,153(2):399-406
Human papillomavirus (HPV) vaccine effectiveness may differ between settings. Here we present the first real-world effectiveness study of HPV vaccination on high-grade cervical lesions from Norway, among women who received HPV vaccine outside the routine program. We performed an observational study of all Norwegian women born 1975 to 1996 and retrieved individual data from nationwide registries on HPV vaccination status and incidence of histologically verified high-grade cervical neoplasia during 2006 to 2016. We estimated the incidence rate ratio (IRR) and 95% confidence intervals (CI) for vaccination vs no vaccination by Poisson regression stratified by age at vaccination <20 years and ≥20 years. The cohort consisted of 832 732 women, of which 46 381 (5.6%) received at least one dose of HPV vaccine by the end of 2016. The incidence rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased with age regardless of vaccination status and was highest at age 25 to 29, at 637/100 000 among unvaccinated women, 487/100 000 among women vaccinated before age 20 and 831/100 000 among women vaccinated at age 20 or older. The adjusted IRR of CIN2+ between vaccinated and unvaccinated women was 0.62 (95% CI: 0.46-0.84) for women vaccinated below age 20, and 1.22 (95% CI: 1.03-1.43) for women vaccinated at age 20 or older. These findings indicate that HPV vaccination among women too old to be eligible for routine HPV vaccination is effective among women who are vaccinated below age 20 but may not have the desired impact among women who are vaccinated at age 20 or older. 相似文献
8.
9.
Yunbao Xu Mengting Zhang Jiaying Zhang Derry Minyao Ng Xiaoxiao Chen Yuexiu Si Yetan Shi Xiangyuan Li Danyi Mao Lu Yang 《Taiwanese journal of obstetrics & gynecology》2021,60(3):433-441
Cervical cancer is a global health challenge in women. Neoadjuvant chemotherapy (NACT) is a recent prospect for alternative cervical cancer treatments. This study investigated the efficacy of NACT against resectable cervical cancer based on the medium and long-term survival of patients with the disease. We searched through PubMed, Web of Science, EBSCO and Cochrane Library for relevant reports published by June 2020. The primary outcomes were 3-year and 5-year progression-free survival (PFS) and overall survival (OS) of patients with resectable cervical cancer. Overall, 22 publications encompassing 5627 patients fulfilled the inclusion criteria. We found NACT not to affect both 3-year PFS and OS as well as 5-year PFS of patients with resectable cervical cancer. However, NACT significantly improves the 5-year OS of patients with resectable cervical cancer (HR = 0.83, 95% CI: 0.73–0.94, p = 0.013). Subgroup analysis (RCTs, non-RCTs, NACT + surgery + AT vs. surgery + AT, NACT + surgery + AT vs. CCRT/RT/CRT) further revealed NACT had no significant effect on 5-year PFS of patients with resectable cervical cancer, converse to the 5-year OS subgroup analysis, which validated the beneficial effect of NACT in patients with resectable cervical cancer. In addition, the effect of NACT was most significant in the non-RCTs subgroup (p = 0.012). NACT may improve the long-term prognosis of patients with resectable cervical cancer. However, further large-scale multicenter studies are needed to validate this finding. 相似文献
10.
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well‐studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization''s gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12–17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Abbreviations
- CC
- cervical cancer
- FVG
- Friuli Venezia Giulia
- HICs
- high‐income countries
- HPV
- human papillomavirus
- LMICs
- middle‐income countries
- WHO
- World Health Organization